IPSS trends for Cs-131 permanent prostate brachytherapy

Brachytherapy

April 1, 2008

Dr. Jones from Danville, PA, reports on 90 patients with prostate cancer treated with Cesium-131 brachytherapy. He and his colleagues conclude that the short half-life of Cesium-131 contributes to a shorter duration of the typical urinary side-effects of brachytherapy

Early Outcomes of Prostate Seed Implants with 131Cs: Toxicity and Initial PSA Dynamics from a Single Institution

Authors: C.S. Platta, D. Khuntia, J. Adkinson, E. Olson, S. Jennifer, H. Odau, R.R. Patel

Is There a Decreased Duration of Acute Urinary and Bowel Symptoms after Prostate Brachytherapy with Cesium 131 Isotope?

Authors: DeFoe SG, et al.

Dosimetric Comparison of Cesium-131 and Palladium-103 for Permanent Prostate Brachytherapy

Authors: J.S. Musmacher, R.T. Byrnes, M. Ghaly, K. Satchwill, L. Rumpf

Cs-131 Prostate Brachytherapy and Treatment Plan Parameters

Authors: Sutlief S and Wallner K

Patient Information

Clinician Information

Cesium 131 Products

Why Theranostics?

Pipeline

IPSS trends for Cs-131 permanent prostate brachytherapy

Authors

Related posts

Early Outcomes of Prostate Seed Implants with 131Cs: Toxicity and Initial PSA Dynamics from a Single Institution

Is There a Decreased Duration of Acute Urinary and Bowel Symptoms after Prostate Brachytherapy with Cesium 131 Isotope?

Dosimetric Comparison of Cesium-131 and Palladium-103 for Permanent Prostate Brachytherapy

Cs-131 Prostate Brachytherapy and Treatment Plan Parameters

Search

Recent Posts

Archives

Company

Brachytherapy

Theranostics

Newsletter

Email newsletter sign-up

Company

Newsletter

Email newsletter sign-up